Abstract Details

Title Non-Amnestic Mild Cognitive Impairment Progresses to Dementia with Lewy Bodies

Topic Aging and Dementia

Presentation(s) S24 - (-)

Poster/Presentation
Number 002

Objective

Background MCI represents an early stage of cognitive dysfunction in those who eventually develop dementia.

Design/Methods We identified consecutive patients followed longitudinally from the Mayo Alzheimer's Disease Research Center with a diagnosis of single or multi-domain, amnestic or non-amnestic MCI. All patients underwent annual formal neurocognitive evaluation. Annual informant-based activities of daily living scales were completed. Progression to a DLB or AD diagnosis using established criteria was estimated as events per 100 person-years of follow-up, and compared between groups, using incidence density methods.

Results Out of 337 patients with an initial diagnosis of MCI, 116 remained as MCI, 49 progressed to DLB, 162 progressed to AD, and 10 progressed to other dementias. Patients were followed between 2 and 12 years. Those who progressed to dementia did not differ in follow-up years (5.2 ± 2.5 years), or age (73.5 ± 7.5 years). The DLB cohort was disproportionately male (DLB 83.7% vs. AD 51.9% vs. Other 60%). Non-amnestic (single or multi-domain) MCI progressed to DLB at a rate of 23.3 events per 100 person years, and to AD at a rate of 2.1 events per 100 person years. Amnestic MCI (single or multi-domain) progressed to DLB at an annual rate of 1.0 events per 100 person years, and to AD at a rate of 17.1 events per 100 person years. The non-amnestic domains in those progressing to DLB represented attention and visuospatial skills.

Conclusions Patients with non-amnestic MCI (single or multi-domain) were more likely to develop DLB than AD, and conversely, patients with amnestic MCI were more likely to develop AD.

Authors/Disclosures
Tanis J. Ferman, PhD (Mayo Clinic Jacksonville) PRESENTER	Ms. Ferman has nothing to disclose.
	No disclosure on file
	No disclosure on file
Kejal Kantarci, MD (Mayo Clinic)	The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF.
Bradley F. Boeve, MD, FAAN (Mayo Clinic)	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville)	The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Ryan J. Uitti, MD, FAAN (Mayo Clinic of Jacksonville)	Dr. Uitti has nothing to disclose.
Zbigniew K. Wszolek, MD, FAAN (Mayo Clinic- Jacksonville)	Dr. Wszolek has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Polish Neurological Society/Via Medica.
Jay A. Van Gerpen, MD, FAAN (Neurology Consultants of Huntsville)	No disclosure on file
Otto Pedraza (Mayo Clinic)	The institution of Otto Pedraza has received research support from Alzheimer's Association. Otto Pedraza has received publishing royalties from a publication relating to health care.
David S. Knopman, MD, FAAN (Mayo Clinic)	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Dennis W. Dickson, MD (Mayo Clinic)	Dr. Dickson has nothing to disclose.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic)	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Dean M. Wingerchuk, MD, FAAN (Mayo Clinic)	Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.

��ɫ��

��ɫ��